CMS
ARKG icon

Capital Market Strategies’s ARK Genomic Revolution ETF ARKG Stock Holding History

Capital Market Strategies’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,372
Closed -$214K – 157
2024
Q3 		$214K Sell
8,372
-629
-7% -$16K 0.13% 137
2024
Q2 		$211K Sell
9,001
-243
-3% -$6.13K 0.13% 139
2024
Q1 		$266K Sell
9,244
-405
-4% -$12.2K 0.2% 113
2023
Q4 		$317K Sell
9,649
-135
-1% -$3.67K 0.28% 93
2023
Q3 		$259K Sell
9,784
-510
-5% -$16.7K 0.26% 103
2023
Q2 		$351K Sell
10,294
-515
-5% -$16.2K 0.32% 80
2023
Q1 		$325K Buy
10,809
+350
+3% +$10.8K 0.58% 33
2022
Q4 		$295K Sell
10,459
-441
-4% -$14K 0.32% 87
2022
Q3 		$358K Sell
10,900
-348
-3% -$12.8K 0.4% 68
2022
Q2 		$354K Sell
11,248
-396
-3% -$13.8K 0.37% 74
2022
Q1 		$535K Buy
11,644
+999
+9% +$47.6K 0.46% 54
2021
Q4 		$652K Buy
+10,645
New +$736K 0.54% 45

Other funds holding ARKG

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Capital Market Strategies's ARKG Position: Q4 2024 in Review

Capital Market Strategies sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2024, closing a stake of 8,372 shares — an estimated $214K sold.

Capital Market Strategies first reported a position in ARKG in Q4 2021 and held it in 12 quarters. The position peaked at $652K in Q4 2021. 240 funds tracked by Wall St. Rank hold ARKG as of Q4 2024.

  • Capital Market Strategies reported no remaining ARK Genomic Revolution ETF position as of Q4 2024 after selling out during the quarter.
  • Capital Market Strategies sold 8,372 ARK Genomic Revolution ETF shares in Q4 2024, an estimated $214K.
  • Capital Market Strategies first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 12 quarters.
  • Capital Market Strategies's ARK Genomic Revolution ETF position peaked at $652K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2024.

Based on Capital Market Strategies's 13F filing for Q4 2024, filed 6 Jan 2025.